Unigene Laboratories has entered into a development services and clinical supply agreement with GlaxoSmithKline (GSK), as part of an exclusive worldwide licensing agreement.
Under the agreement, Unigene will receive up to $2.2m in payments from GSK to conduct certain development and manufacturing activities.
The activities are related to the active pharmaceutical ingredient and finished drug product for an oral formulation of a recombinantly produced investigational parathyroid hormone (PTH) analogue to treat osteoporosis in postmenopausal women in advance of GSK’s potential decision to study the molecule in a Phase 3 programme.
Unigene’s oral PTH is currently in a Phase 2 study and the results are expected before the year’s end.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData